10:37 AM EDT, 08/07/2024 (MT Newswires) -- NewAmsterdam Pharma ( NAMS ) shares were about 1.8% lower in early trading Wednesday after the late-stage biopharmaceutical company narrowed its Q2 loss amid higher revenue.

The firm reported a Q2 net loss of $0.41 per diluted share, narrower than a net loss of $0.47 per share a year earlier.

Analysts polled by Capital IQ expected a loss of $0.54 per share.

Revenue for the quarter ended June 30 was $2.3 million, compared with $1.7 million a year earlier.

Analysts surveyed by Capital IQ expected $1.1 million.

Price: 15.94, Change: -0.29, Percent Change: -1.79